Home › Ventricular Tachycardia › NCT05377216
Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation
RecruitingEarly phase 1
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Planned catheter based VT ablation * Age at least 18 years Exclusion Criteria: * Pregnancy * Contraindication to SGB or VT ablation * Hypersensitivity of local anesthetic of amide type * Hemodynamic instability during the procedure prior to the study protocol
About the study
Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.
What is being tested
- Stellate Ganglion Block (drug)
Sponsor: University of Pennsylvania · Participants: 20 · Started: Sep 1, 2022
Contact the study team
- Timothy Markman, MD · Phone: 267-593-0103
Official record on ClinicalTrials.gov — NCT05377216
Locations in the U.S.
| Pennsylvania | Hospital of the University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.